Please login to the form below

Not currently logged in
Email:
Password:

Metrion Biosciences adds to its board

Dr Barry Kenny and Dr Andrew Southan join the company

Metrion Biosciences, the specialist ion channel contract research and drug discovery group, has appointed Dr Barry Kenny and Dr Andrew Southan to its board of directors, a move that will see the group strengthen the company’s focus on commercial and business development capabilities.

Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

He has held roles for Paradigm Therapeutics and Pfizer.

Dr Southan joined Metrion as head of commercial operations in October 2016, and was promoted to chief operating officer in April 2017.

He has over 25 years’ experience in ion channel research and development and has held roles for Wyeth Research and Ionix Pharmaceuticals.

Dr Keith McCullagh, non-executive chairman of Metrion Biosciences, said: “I am delighted to welcome both Barry and Andy to Metrion’s board of directors.

“Barry’s substantial experience of drug discovery deal-making will be of great value to Metrion as we continue to build our worldwide CRO and collaboration business, and Andy’s dedication to Metrion’s client service and quality of operations has been a major factor of growth of the business.”

20th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics